Characterization of CFTR modulators mechanism of action via Photo-Affinity Labeling (PAL) approach

Search for drug combinations killing Mycobacterium abscessus in cystic fibrosis

Multiomics exploration of the CF primary bronchial epithelium lipidome and its role on CFTR rescue

Harnessing CRISPR-Cas technology to revert F508del and 2789+5G>A CFTR defects

Toward the development of tailored therapies for insensitive CF gating mutations

Oxidative stress and autophagy in Cystic Fibrosis: Novel biochemical characterizations and drug discovery approaches

In vitro evaluation of novel sequence-specific RNA editing tools to rescue nonsense mutant CFTR transcript

Enhancing the prediction of clinical responses to CFTR modulators by in vitro assays using patient-derived tissues under conditions mimicking native status of CF airways

Monocyte integrin activation as a cystic fibrosis drug evaluation test: validation phase

Theratyping of cystic fibrosis

Lead optimization of MKT-077 analogues as HSP70 allosteric inhibitors combined with F508del CFTR correctors: a multi-drug approach to contrast cystic fibrosis

Theratyping orphan mutations in Italian cystic fibrosis patients: meeting unmet needs

Alternative targets for the treatment of cystic fibrosis basic defect

Pharmacological inhibition of colistin resistance in Gram-negative cystic fibrosis pathogens

Probiotics: an emerging strategy to fight bacterial pulmonary infections in CF

Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against Pseudomonas aeruginosa

Tackling phage resistance to increase the robustness of phage therapy for curing Pseudomonas aeruginosa infections in patients with cystic fibrosis (PhaCyf)

Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease

New drug combinations against non-tuberculous mycobacteria infections in cystic fibrosis

New weapons against Mycobacterium abscessus and other nontuberculous Mycobacteria

Exploring the dual targeting of host and microbial sphingosine-1-phosphate lyase as antimicrobial strategy in cystic fibrosis

Nanotechnology-based Resolvin D1 as Proresolving Therapy in Cystic Fibrosis: Preclinical Studies for the Delivery of Innovative Formulations to the Clinic

Mental Health in cystic fibrosis patients: the prognostic role of temperament, personality and attachment styles

Peptide-nucleic acids as potential CFTR amplifier molecules for cystic fibrosis treatment

Lipid-based therapeutic strategies to optimize the effectiveness of innovative drugs to rescue F508del-CFTR

Small nitrogen heterocycles as correctors of the mutant CFTR protein in cystic fibrosis

Characterization of CFTR modulators mechanism of action via Photo-Affinity Labeling (PAL) approach

Intestinal organoids for assessment and pharmacological correction of abnormalities in fluid transport and anion currents in patients affected by pancreatitis

Validation of the distribution and activity of new optimized leads in mouse model and other CF model systems

Functional role of post-translational modifications in F508del-CFTR correction

Establishment of Conditionally Reprogrammed Airway Epithelial Stem Cell cultures from nasal epithelia of Cystic Fibrosis patients: exploring response to CFTR-modulating drugs for correlation with genetic profile (theratyping) and restoring CFTR function through gene editing approaches

Theratyping of rare CFTR genotypes for treatment with CFTR modulators

Targeting small RNA-mediated regulation of virulence and antibiotic resistance to develop non-traditional therapeutic options against Pseudomonas aeruginosa

Disrupting Pseudomonas aeruginosa Quorum Sensing signalling in Cystic Fibrosis patients as a new frontier for antibacterial therapy

New drug combinations against non-tuberculous mycobacteria infections in cystic fibrosis

Can old and new sweet glycomimetics act as antibacterial and antibiofilm agents in the treatment of CF lung disease infections?

New weapons against Mycobacterium abscessus and other nontuberculous mycobacteria

Targeting the STING/Transglutaminase 2-regulated Interferon response as a novel host-direct approach to fight bacterial infections in Cystic Fibrosis

Exploring the dual targeting of host and microbial sphingosine-1-phosphate lyase as antimicrobial strategy in cystic fibrosis

Oral and pulmonary delivery platforms for anakinra repurposing in cystic fibrosis

Counteracting inflammation triggered by P. aeruginosa-activated lung-infiltrating Th1/17 cells: a novel approach for precision medicine in CF

Nanotechnology-based Resolvin D1 as Proresolving Therapy in Cystic Fibrosis: Preclinical Studies for the Delivery of Innovative Formulations to the Clinic

Harnessing selective histone deacetylase 6 (HDAC6) inhibition to tackle inflammation and fibrotic remodeling in cystic fibrosis

Use of multivolume MRI to assess response to CFTR modulators

Role of viable but non culturable (VBNC) bacterial forms in CF patients in a clinical setting: a translational research

Unravelling novel biomarkers to define the progression of Mycobacterium abscessus lung disease in cystic fibrosis

Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): an Italian multicenter survey evaluating prevalence, clinical data, management and outcome